Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

Arai Taeang; Atsukawa Masanori; Tsubota Akihito; Ikegami Tadashi; Shimada Noritomo; Kato Keizo; Abe Hiroshi; Okubo Tomomi; Itokawa Norio; Kondo Chisa; Mikami Shigeru; Asano Toru; Chuganji Yoshimichi; Matsuzaki Yasushi; Toyoda Hidenori; Kumada Takashi; Iio Etsuko; Tanaka Yasuhito; Iwakiri Katsuhiko

首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

【24h】

Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

机译：关于慢性肾病的基因型1B慢性丙型肝炎患者的疗效和安全性的疗效和安全性的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimThe aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD).

机译：本研究的目的是阐明常规血液/ ParitaPrevir / Ritonavir（obs / PTV / R）治疗在基因型1B慢性丙型肝炎患者中的疗效和安全性的疗效和安全性。

著录项

来源
《Hepatology research: the official journal of the Japan Society of Hepatology》 |2018年第7期|共7页
作者
Arai Taeang; Atsukawa Masanori; Tsubota Akihito; Ikegami Tadashi; Shimada Noritomo; Kato Keizo; Abe Hiroshi; Okubo Tomomi; Itokawa Norio; Kondo Chisa; Mikami Shigeru; Asano Toru; Chuganji Yoshimichi; Matsuzaki Yasushi; Toyoda Hidenori; Kumada Takashi; Iio Etsuko; Tanaka Yasuhito; Iwakiri Katsuhiko;
展开▼
作者单位

Chiba Hokusoh Hosp Nippon Med Sch Div Gastroenterol Dept Internal Med Inzai Chiba Japan;

Chiba Hokusoh Hosp Nippon Med Sch Div Gastroenterol Dept Internal Med Inzai Chiba Japan;

Jikei Univ Sch Med Core Res Facil Basic Sci Tokyo Japan;

Tokyo Med Univ Ibaraki Med Ctr Div Hepatol &

Gastroenterol Dept Internal Med Inashiki Ibaraki;

Otakanomori Hosp Div Gastroenterol &

Hepatol Dept Internal Med Kashiwa Chiba Japan;

Shinmatsudo Cent Gen Hosp Div Gastroenterol &

Hepatol Dept Internal Med Matsudo Chiba Japan;

Shinmatsudo Cent Gen Hosp Div Gastroenterol &

Hepatol Dept Internal Med Matsudo Chiba Japan;

Chiba Hokusoh Hosp Nippon Med Sch Div Gastroenterol Dept Internal Med Inzai Chiba Japan;

Chiba Hokusoh Hosp Nippon Med Sch Div Gastroenterol Dept Internal Med Inzai Chiba Japan;

Nippon Med Sch Div Gastroenterol &

Hepatol Dept Internal Med Tokyo Japan;

Kikkoman Gen Hosp Div Gastroenterol Dept Internal Med Noda Chiba Japan;

Tokyo Metropolitan Bokutoh Hosp Div Gastroenterol &

Hepatol Dept Internal Med Tokyo Japan;

Tokyo Metropolitan Bokutoh Hosp Div Gastroenterol &

Hepatol Dept Internal Med Tokyo Japan;

Tokyo Med Univ Ibaraki Med Ctr Div Hepatol &

Gastroenterol Dept Internal Med Inashiki Ibaraki;

Ogaki Municipal Hosp Dept Gastroenterol Ogaki Japan;

Ogaki Municipal Hosp Dept Gastroenterol Ogaki Japan;

Nagoya City Univ Grad Sch Med Sci Dept Virol Nagoya Aichi Japan;

Nagoya City Univ Grad Sch Med Sci Dept Virol Nagoya Aichi Japan;

Nippon Med Sch Div Gastroenterol &

Hepatol Dept Internal Med Tokyo Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
chronic hepatitis C; chronic kidney disease; direct-acting antiviral; genotype 1; ombitasvir; paritaprevir; ritonavir;

机译：慢性丙型肝炎;慢性肾病;直接作用抗病毒;基因型1;Obsitasvir;ParitaPrevir;ritonavir;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease [J] . Arai Taeang, Atsukawa Masanori, Tsubota Akihito, Hepatology research: the official journal of the Japan Society of Hepatology . 2018,第7期

机译：关于慢性肾病的基因型1B慢性丙型肝炎患者的疗效和安全性的疗效和安全性的疗效和安全性
2. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C [J] . Atsukawa Masanori, Tsubota Akihito, Koushima Yohei, Hepatology research: the official journal of the Japan Society of Hepatology . 2017,第13期

机译：透析1B慢性丙型肝炎透析患者的透析患者的疗效和安全性的疗效和安全性
3. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis [J] . Lawitz Eric, Makara Mihaly, Akarca Ulus Salih, Gastroenterology . 2015,第4期

机译：Ombitasvir，Paritaprevir和Ritonavir在有和没有肝硬化的基因型1b慢性丙型肝炎病毒感染患者的开放标签研究中的功效和安全性
4. The Natural History of Chronic Kidney Disease Revisited-A 72-Month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on End-Stage Renal Disease and Death Rates in 100 High-Risk Chronic Kidney Disease Patients: A Call for Circumspection [C] . Macaulay A.C. Onuigbo Conference on Peritoneal Dialysis . 2009

机译：慢性肾病的自然历史重新审议-A 72个月的MASO卫生系统高血压诊所的研究网络网络前期肾病和死亡率100个高危慢性肾病患者的死亡率：一个呼吁守则
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials [O] . Jason Grebely, Massimo Puoti, Heiner Wedemeyer, 2018

机译：Ombitasvir / Paritaprevir / Ritonavir和Dasabuvir联合或不联合利巴韦林在接受阿片类药物替代治疗的慢性丙型肝炎病毒基因型1感染患者中的疗效和安全性：对12项临床试验的事后分析
7. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis [O] . Lawitz Eric, Makara Mihály, Akarca Ulus Salih, 2015

机译：Ombitasvir，Paritaprevir和Ritonavir在有和没有肝硬化的基因型1b慢性丙型肝炎病毒感染患者的开放标签研究中的功效和安全性

Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

摘要

著录项

相似文献

相关主题

期刊订阅